CEVEC is a leading biotechnology company specializing in high-performance cell technology for the manufacturing of advanced biotherapeutics. The company offers a range of platform technologies designed for gene therapy vectors, vector vaccines, and complex recombinant proteins. CEVEC's technology is particularly noted for its application in the viral vector space, where it is the technology of choice for Adeno-Associated Virus (AAV) manufacturing. The company's Ad Technology is also highly regarded for producing RCA-free adenoviral vectors. Additionally, CEVEC's Go technology enables the production of complex and highly glycosylated recombinant proteins.

CEVEC serves a diverse range of clients in the biotechnology and pharmaceutical sectors, providing solutions from research and development (R&D) to full-scale manufacturing. The company operates in the global biotherapeutics market, which is characterized by rapid innovation and high growth potential. CEVEC's business model is based on licensing its proprietary technologies and offering contract manufacturing services. Revenue is generated through licensing fees, royalties, and service contracts.

The company was recently acquired by Cytiva, a move that strengthens its capabilities in cell line development. Dr. Nicole Faust, who has over 20 years of experience in the biotechnology sector, leads the company. She holds a PhD in cell and molecular biology and an MBA, bringing a strong scientific and managerial background to the organization.

Keywords: cell technology, biotherapeutics, gene therapy, AAV manufacturing, adenoviral vectors, recombinant proteins, biotechnology, pharmaceutical, licensing, contract manufacturing.